PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26844012-0	2016	Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients.	1-oh-midazolam	92-106	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-71	
26844012-1	2016	This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1-OH-midazolam in morbidly obese patients receiving oral and i.v.	1-oh-midazolam	118-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-89	
26844012-1	2016	This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1-OH-midazolam in morbidly obese patients receiving oral and i.v.	1-oh-midazolam	118-132	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96	
20798939-7	2011	RESULTS: CYP3A activity was clearly induced when assessed a day after docetaxel administration as shown by lower midazolam AUC (P < 0.0001) and higher AUC ratio (1-OH-midazolam/midazolam, P = 0.018).	1-oh-midazolam	165-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	9-14	
19838691-1	2010	PURPOSE: In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG) is also decreased.	1-oh-midazolam	71-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	95-114	
19838691-1	2010	PURPOSE: In preterm infants, the biotransformation of midazolam (M) to 1-OH-midazolam (OHM) by cytochrome P450 3A4 (CYP3A4) is developmentally immature, but it is currently unknown whether the glucuronidation of OHM to 1-OH-midazolam glucuronide (OHMG) is also decreased.	1-oh-midazolam	71-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	116-122